Tapdi Oksijen Ozel Saglik ve Egitim Hizmetleri Sanayi Ticaret AS
Tapdi Oksijen provides pharmaceutical and healthcare services, primarily generating revenue through the production and distribution of oxygen-related medical products and healthcare education services.
Business. Tapdi Oksijen Ozel Saglik ve Egitim Hizmetleri Sanayi Ticaret AS (TNZTP.IS) is a healthcare services and equipment company primarily engaged in healthcare facilities and services, with activities including pharmaceuticals. The firm operates on a service-revenue model within the broader healthcare sector. Specific details regarding operating segments and geographic presence are not disclosed. The company is listed on the Borsa Istanbul.
At a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
Tapdi Oksijen Ozel Saglik ve Egitim Hizmetleri Sanayi Ticaret AS (TNZTP.IS) is a healthcare services and equipment company primarily engaged in healthcare facilities and services, with activities including pharmaceuticals. The firm operates on a service-revenue model within the broader healthcare sector. Specific details regarding operating segments and geographic presence are not disclosed. The company is listed on the Borsa Istanbul.
The company maintains a strong capital structure with a debt-to-equity ratio of 0.05, indicating a low reliance on debt financing. However, its liquidity position is rated as medium, with negative net cash after subtracting total debt, suggesting potential short-term liquidity constraints. The company's return on equity (ROE) of 8.69% and return on assets (ROA) of 7.27% are both above the industry median, reflecting efficient use of equity and assets to generate returns.
Profitability is robust, with a gross profit margin of 40.98% and an operating margin of 28.37%, both of which are strong indicators of cost control and pricing power. The company's net income margin of 20.29% is also well above the industry median, suggesting a healthy bottom line. These metrics align with the industry's preferred focus on operating efficiency and asset utilization.
The company's revenue is concentrated in a single business segment, with no disclosed geographic diversification. This lack of diversification increases exposure to regional economic or regulatory shifts, which could impact revenue stability. The absence of segment or geographic breakdowns in the financial data limits the ability to assess risk distribution across different markets or product lines.
Looking ahead, the company is projected to maintain a stable growth trajectory, with revenue expected to remain consistent in the current fiscal year and potentially increase in the following year. The free cash flow of 614.91 million TRY supports reinvestment or shareholder returns, though the negative operating cash flow of -443.55 million TRY raises concerns about short-term cash generation.
The risk assessment highlights a medium liquidity risk due to the negative net cash position after debt, which could constrain operational flexibility. The dilution risk is rated as low, with no significant dilution expected in the near term. However, the company's reliance on free cash flow for growth may necessitate future capital raising, which could introduce dilution pressure.
Recent filings and transcripts do not provide specific details on strategic initiatives or major events, but the company's financial performance suggests a focus on maintaining profitability and managing debt levels. The absence of recent major announcements or regulatory actions indicates a relatively stable operating environment.
- The company has a strong ROE and ROA, indicating efficient capital use and asset management.
- A low debt-to-equity ratio suggests a conservative capital structure.
- Negative net cash after debt raises liquidity concerns despite a medium liquidity risk rating.
- Revenue concentration in a single segment increases exposure to market-specific risks.
- Free cash flow is positive, supporting potential reinvestment or shareholder returns.
Bull / Bear case
Generated · model-assistedIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Estimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- Net cash is negative after subtracting total debt.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Capex To Revenuecapital_expenditure / revenue
- Return On Equitynet_income / total_equity
- Debt To Equity(short_term_debt + long_term_debt) / total_equity
- Cash Conversion Ratiooperating_cash_flow / net_income
- Tapdi Oksijen Ozel Saglik ve Egitim Hizmetleri Sanayi Ticaret AS Market data — financials · 2026-05-29